Resources
7 Results (showing 1 - 7)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV plenary session was held in the Independence Ballroom on Wednesday, March 5, 2020, at 4:00 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout session was held in the Independence Ballroom on Wednesday, March 4, 2020, at 4:15 PM.
Posted 5/18/2020 (updated 3/28/2024)
Overreliance on opioid medications is emblematic of a health care system that incentivizes quick, simplistic answers to complex physical and mental health needs.
Posted 9/4/2020 (updated 3/29/2024)
Like all professions, the addictions treatment field is faced with the challenges of employee substance use and abuse and their impact on retention of quality staff. Because the addictions field employees a disproportionate number of individuals – by recent estimates close to half of the treatment workforce – in recovery, the field faces particular retention challenges. This toolkit provides meaningful and practical guidance to the problem of substance misuse among addictions professionals.
Posted 2/10/2021 (updated 4/4/2024)
The Opioid Response Network is making available a new dental curriculum on SBIRT (screening, brief intervention and referral to treatment), an evidence-based approach to managing patients with or at risk of developing a substance use disorder (SUD).
The curriculum was developed for dentists by the ORN grant through a collaboration with the American Academy of Addiction Psychiatry and the Division on Substance Use Disorders, Columbia University Irving Medical Center/NYSPI.
Posted 2/23/2021 (updated 4/4/2024)
RCORP Planning 3 Reference Guide
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).